[Effect of long-term continuous methimazole treatment of thyrotoxicosis: comparison with radioiodine]
IJEM-Iranian Journal of Endocrinology and Metabolism. 2011; 12 (5): 466-475
en En, Fa
| IMEMR
| ID: emr-112806
Biblioteca responsable:
EMRO
ABSTRACT
The major complication of radioiodine therapy for thyrotoxicosis is hypothyroidism, the long-term management of which is often problematic. In this study, the long-term effects of continuous methimazole [MMI] therapy are investigated. One hundred and thirty-two patients, aged between 36-66 years, with Graves recurrence, were semi randomly randomized in 2 groups for continuous antithyroid and radioiodine treatment. The number of thyroid dysfunctions in each patient were recorded and serum TSH, FT4, Anti TPO, TRAb, FBS, HOMA IR, and lipid profiles were measured. Bone mineral density and echocardiography were performed. There was no significant differences in age, duration of symptoms and thyroid function between the 2 groups. No serious complications occurred in the MMI group and no difference in any of parameters was seen between groups 1 and 2. Goiter rate and anti TPO concentration were higher in group 1 than in group 2. Serum triglycerides and cholesterol were increased in group 2 as compared to group 1. Bone mineral density was more reduced in group 2, especially in the spine. Echocardiography showed diastolic dysfunction in group 2 as compared to group 1. Some parameters in neuro-pschyciatric evaluation were significantly better in the MMI group, as compared to the radioiodine one. Considering it is a safe treatment and has fewer complications, methimazole is another option for patients with recurrent Graves', who do not wish to use radioiodine
Buscar en Google
Índice:
IMEMR
Asunto principal:
Recurrencia
/
Tirotoxicosis
/
Enfermedad de Graves
/
Resultado del Tratamiento
/
Hipotiroidismo
/
Radioisótopos de Yodo
Límite:
Humans
Idioma:
En
/
Fa
Revista:
Iran. J. Endocrinol. Metab.
Año:
2011